MS General Surgery - University Examination Answers

---

QUESTION 1 (30 marks)

Pathophysiological Changes in Laparoscopic Surgery and Prevention of Related Complications

---

INTRODUCTION

---

I. PNEUMOPERITONEUM: CREATION AND BASICS

• Standard intraabdominal pressure (IAP): 12-15 mmHg (working pressure); up to 20 mmHg used occasionally
• CO2 is the gas of choice because it is:
  • Non-flammable (safe with electrocautery)
  • Highly soluble in blood (rapidly absorbed and excreted via lungs)
  • Inexpensive and readily available
• Introduced via Veress needle or Hasson (open) technique

---

II. CARDIOVASCULAR EFFECTS

A. Effect of Increased IAP

• Increased systemic vascular resistance (SVR) due to neurohumoral activation (renin-angiotensin-aldosterone, vasopressin release)
• Decreased cardiac output (5-30% reduction)
• Increased mean arterial pressure
• Increased heart rate (reflex from vagal stimulation or CO2 absorption)
• Decreased portal and hepatic blood flow (up to 40%)
• Decreased renal blood flow and GFR

B. CO2 Absorption Effects

• Absorbed CO2 causes hypercapnia and acidosis
• Hypercarbia causes peripheral vasodilation but pulmonary vasoconstriction
• Stimulates sympathetic system → tachycardia, hypertension, arrhythmias

C. Position-Related Effects

• Trendelenburg (pelvis up): Increases cardiac output, increases intracranial and intraocular pressure, increases risk of regurgitation
• Reverse Trendelenburg (head up): Decreases cardiac output and venous return, pooling in lower limbs

---

III. RESPIRATORY EFFECTS

1. Diaphragm elevation due to raised IAP → reduced functional residual capacity (FRC)
2. Increased airway resistance and peak airway pressure
3. Ventilation-perfusion (V/Q) mismatch - dependent lung zones become relatively underventilated
4. CO2 absorption from peritoneum → hypercapnia → respiratory acidosis
5. In spontaneously breathing patients: risk of hypercarbia and CO2 narcosis
6. CO2 embolism - rare but life-threatening; causes acute cardiovascular collapse
7. Endobronchial intubation risk in steep Trendelenburg (cephalad shift of carina)

---

IV. RENAL EFFECTS

1. Raised IAP compresses renal vasculature → decreased renal blood flow (up to 60%)
2. Decreased GFR and urine output (oliguria common; not true renal failure)
3. Elevated antidiuretic hormone (ADH) and aldosterone levels → sodium and water retention
4. Mechanism: direct compression + neurohormonal activation + decreased cardiac output
5. Usually reversible on desufflation

---

V. NEUROHUMORAL AND METABOLIC EFFECTS

1. Cortisol, catecholamines, growth hormone levels increase (stress response, but less than in open surgery)
2. Vasopressin (ADH) markedly elevated - causes vasoconstriction and oliguria
3. Renin-Angiotensin-Aldosterone System (RAAS) activated by renal hypoperfusion
4. CO2 absorption → carbonic acid formation → metabolic and respiratory acidosis
5. Immunological advantage: Laparoscopy preserves immune function better than open surgery (reduced cytokine release, better NK cell preservation)

---

VI. EFFECTS ON THE PORTAL AND SPLANCHNIC CIRCULATION

1. Portal blood flow decreases by 35-40% at 15 mmHg IAP
2. Liver blood flow decreases → risk in patients with pre-existing hepatic disease
3. Mesenteric ischemia is possible at high IAP
4. Bowel wall ischemia rare but can occur with IAP >20 mmHg

---

VII. NEUROLOGICAL EFFECTS

1. Increased intracranial pressure (ICP): Trendelenburg position + CO2 absorption + raised IAP all contribute
2. Increased intraocular pressure
3. Contraindicated/used with caution in: raised ICP (head injury, VP shunt), glaucoma

---

VIII. THROMBOTIC AND HAEMATOLOGICAL EFFECTS

1. Venous stasis in lower limbs due to raised IAP + positioning
2. Deep vein thrombosis (DVT) and pulmonary embolism (PE) risk increased
3. Venous stasis causes activation of coagulation cascade
4. Fibrinolysis is better preserved in laparoscopy vs open surgery

---

IX. SPECIFIC COMPLICATIONS AND PREVENTION

A. Entry-Related Complications

B. CO2-Related Complications

C. Cardiovascular Complications

• Arrhythmias: pre-oxygenate, maintain normocarbia, avoid vagal stimulation
• Hypotension: reduce IAP, fluid resuscitation, vasopressors if needed
• DVT: pneumatic compression stockings, LMWH, early mobilization

D. Trocar Site Complications

E. Physiological Precautions

1. Patient selection: Contraindications include severe COPD, uncorrected coagulopathy, bowel obstruction with massive distension, hemodynamic instability
2. Low IAP technique: Gasless laparoscopy (abdominal wall lift) in high-risk patients
3. ETCO2 monitoring: Maintain 35-40 mmHg by adjusting ventilation
4. IAP monitoring: Maintain <15 mmHg; desufflate if cardiovascular compromise
5. Head-down position: Minimize time in steep Trendelenburg; use ramp positioning
6. Intermittent pneumatic compression devices: Applied before induction
7. Warm, humidified CO2: Reduces hypothermia, reduces peritoneal damage

---

X. ADVANTAGES OF LAPAROSCOPY OVER OPEN SURGERY (Physiological Basis)

• Smaller incisions → less pain, less ileus, faster return of gut function
• Reduced wound infection, incisional hernia rates
• Reduced blood loss and fluid shifts
• Better preservation of immunity (less IL-6, TNF-alpha release)
• Faster recovery and shorter hospital stay

---

---

QUESTION 2 (10 marks)

Professional Hazards of Surgeons

---

I. PHYSICAL HAZARDS

A. Musculoskeletal Disorders

• The most common occupational hazard (affecting >80% of surgeons)
• Causes: Prolonged standing, static postures, ergonomically poor instrument design (especially laparoscopic instruments)
• Sites: Neck, back (lumbar), shoulders, hands/wrists
• Conditions: Occupational low back pain, cervical spondylosis, carpal tunnel syndrome, de Quervain's tenosynovitis, trigger finger
• Prevention: Ergonomic theatre setup, adjustable table height, anti-fatigue mats, regular stretching, monitor height adjustment in laparoscopy

B. Radiation Hazards

• Exposure during C-arm fluoroscopy (orthopaedic, vascular, endoscopic procedures), nuclear medicine procedures
• Risks: Cumulative DNA damage, cataracts (lens of eye most sensitive), thyroid cancer, leukaemia, dermatitis
• Prevention:
  • Lead aprons (minimum 0.25 mm lead equivalent), thyroid shields, lead glasses
  • Distance (inverse square law)
  • Minimize fluoroscopy time
  • Radiation dosimetry badges (TLD/film badges)
  • Adherence to ALARA principle (As Low As Reasonably Achievable)

C. Noise-Induced Hearing Loss

• Prolonged exposure to theatre equipment (ultrasonic dissectors, suction devices, alarms)

---

II. BIOLOGICAL HAZARDS

A. Bloodborne Pathogen Exposure

• Needle stick injuries and sharps injuries (most common route)
• Pathogens: HIV, HBV, HCV
• Risk per exposure: HIV ~0.3%, HCV ~3%, HBV ~30% (unvaccinated)
• Prevention:
  • Hepatitis B vaccination (mandatory for healthcare workers)
  • Double-gloving (reduces inner glove perforation by 70%)
  • No-touch technique (passing sharps in kidney dish, not hand-to-hand)
  • Blunt-tip needles for closure
  • Puncture-resistant gloves for high-risk procedures
  • Post-exposure prophylaxis (PEP) for HIV within 72 hours

B. Surgical Smoke Hazards

• Electrocautery, laser, and ultrasonic devices generate surgical plume
• Contains: viral DNA/RNA (HPV has been detected), carcinogenic particles (benzene, formaldehyde), aerosolized bacteria
• Prevention: Smoke evacuation systems, appropriate masks (N95 for known viral cases)

C. Latex Allergy

• Repeated glove use → sensitization → type I (anaphylaxis) or type IV (contact dermatitis) hypersensitivity
• Prevention: Latex-free gloves, early identification of sensitized individuals

---

III. CHEMICAL HAZARDS

• Glutaraldehyde (instrument sterilization): skin sensitization, asthma, eye irritation
• Anaesthetic gases (nitrous oxide, halogenated agents): chronic exposure → hepatotoxicity, nephrotoxicity, reproductive effects
• Formalin/formaldehyde (pathology handling): carcinogen (nasopharyngeal cancer)
• Methyl methacrylate (bone cement in orthopaedics): sensitizer, teratogen
• Prevention: Adequate ventilation, scavenging systems, PPE, occupational exposure limits (OELs)

---

IV. PSYCHOLOGICAL HAZARDS

---

V. ERGONOMIC AND WORKPLACE HAZARDS

• Fatigue from long operating lists and night calls: Increases error rate (comparable to 0.05% blood alcohol)
• Eye strain: From microscopes, loupes, bright xenon lights
• Hypothermia: Cold theatre environments
• Diathermy/electrosurgical burns: Through faulty equipment

---

VI. MEDICOLEGAL AND ETHICAL HAZARDS

• Risk of litigation, criminal prosecution
• Boundary violations
• Academic integrity issues

---

---

QUESTION 3 (30 marks)

Hand-Sewn vs Stapled Intestinal Anastomosis: Principles, Advantages, Disadvantages, Techniques, and Available Staplers

---

I. PRINCIPLES OF INTESTINAL ANASTOMOSIS

1. Adequate blood supply - the single most important factor
2. Tension-free approximation - mesentery adequately mobilized
3. No distal obstruction
4. Healthy bowel ends - viable, no ischaemia, no inflammation/radiation damage
5. Watertight apposition - mucosa-to-mucosa (inverting) or all-layer (everting) contact
6. No faecal loading - bowel preparation or on-table lavage if needed
7. Good nutritional status (serum albumin >30 g/L)
8. Absence of infection/peritoneal contamination

---

II. HAND-SEWN ANASTOMOSIS

A. Historical Context

B. Types of Sutures Used

• Absorbable: Polyglactin (Vicryl), Polyglycolic acid (Dexon), PDS (polydioxanone)
• Non-absorbable: Prolene (polypropylene) - used for vascular anastomoses

C. Suture Techniques

D. Layers

• Inner layer: Continuous Connell or Vicryl (all layers, inverting)
• Outer layer: Interrupted/continuous Lembert (seromuscular)
• Advantage: More secure, traditional; better in contaminated fields
• Disadvantage: Greater luminal narrowing, more ischaemia, technically more demanding

• Full-thickness interrupted or continuous sutures, usually extramucosal
• Advantage: Less ischaemia, adequate lumen, equal leak rate to two-layer
• Evidence (RCTs) shows no significant difference in leak rate between single and double layer

E. Configuration Options

• End-to-End (EEA): Bowel continuity restored; risk of stricture if size mismatch
• End-to-Side (ESA): Used when size mismatch or end-to-end not feasible (e.g., ileocolic)
• Side-to-Side (SSA): Larger anastomosis, less risk of stricture; standard for Billroth II, Roux-en-Y

F. Advantages of Hand-Sewn Anastomosis

1. No device cost
2. Applicable to any bowel caliber, any configuration
3. Surgeon has tactile feedback and can assess tissue quality
4. Possible in difficult anatomical locations (deep pelvis, oesophageal anastomosis)
5. Safer in contaminated/hostile fields
6. Allows fine tissue adjustment, especially with size discrepancy
7. Does not leave foreign material (metal staples) in situ

G. Disadvantages of Hand-Sewn Anastomosis

1. Technically demanding - steep learning curve
2. Time-consuming
3. Requires adequate exposure
4. Greater intraoperative bowel handling and spillage risk
5. Increased operating time increases anaesthetic risk
6. More technically variable (operator-dependent)

---

III. STAPLED ANASTOMOSIS

A. Historical Context

B. Mechanism

C. Techniques of Stapled Anastomosis

• Used for colorectal, oesophagogastric anastomoses
• Anvil placed in proximal bowel with purse-string suture
• Stapler body inserted transanally (or via gastrotomy)
• Stapler fires: creates double-staggered row of staples + cuts out donuts
• "Donuts" (tissue rings) inspected for completeness
• Leak test mandatory with air or methylene blue

• Most common technique for ileocolic and small bowel anastomoses
• Both ends of bowel held parallel; enterotomies made on antimesenteric borders
• GIA/linear cutter stapler inserted and fired (creates side-to-side anastomosis)
• Common enterotomy closed with linear (TA) stapler or hand-sewn
• Creates a wide, well-vascularised anastomosis with low leak rate

• Used for Billroth II, jejunojejunostomy in Roux-en-Y

D. Advantages of Stapled Anastomosis

1. Faster - significantly reduces operative time
2. Reproducible - less operator-dependent
3. Enables low pelvic and intrathoracic anastomoses - areas inaccessible to hand suturing
4. Uniform staple formation - consistent tissue inversion and haemostasis
5. Less bowel handling - reduced spillage and contamination
6. Creates a wider lumen (especially functional EEA)
7. Better for laparoscopic surgery - hand suturing difficult intracorporeally
8. Equal or superior leak rates compared to hand-sewn in many series
9. Reduced operative blood loss

E. Disadvantages of Stapled Anastomosis

1. Expensive (cost per stapler: Rs 3,000-15,000 in India)
2. Stricture formation - especially circular staplers (EEA); incidence 5-20%
3. Staple line bleeding - if not properly compressed
4. Incomplete donuts indicate defective anastomosis
5. Cannot be used in very small bowel (<2 cm diameter)
6. Not ideal in grossly contaminated fields (staples do not fire well in friable tissue)
7. Device malfunction - misfires, incomplete staple formation, knife failure
8. Foreign body - titanium staples remain permanently
9. Learning curve for correct deployment

---

IV. COMPARISON TABLE: HAND-SEWN vs STAPLED

---

V. STAPLERS AVAILABLE FOR INTESTINAL ANASTOMOSIS

A. Linear Staplers (TA - Thoracoabdominal / Roticulator)

B. Circular Staplers (EEA - End-to-End Anastomosis)

C. Endoscopic (Laparoscopic) Staplers

D. Specialty Staplers

---

VI. SPECIFIC APPLICATIONS

---

---

QUESTION 4 (10 marks)

Replantation of Limb

---

I. DEFINITION

---

II. HISTORY

• 1962: Malt and McKhann - first successful upper limb replantation (12-year-old boy, arm amputated by train)
• 1968: Komatsu and Tamai - first successful digital replantation
• Modern replantation uses the operating microscope and microsurgical instruments for anastomosis of vessels 1-3 mm in diameter

---

III. INDICATIONS (what to replant)

• Thumb amputation (thumb constitutes 40-50% of hand function; virtually always indicated)
• Multiple digit amputations
• Amputation through palm or wrist
• Pediatric amputations (excellent recovery potential)
• Isolated single-digit amputation distal to FDS insertion (zone I)
• Major upper limb amputations (arm, forearm, elbow level)

• Isolated single digit (zone II - controversial, poorer results)
• Lower limb amputations - more controversial (poor functional recovery, high morbidity)

---

IV. CONTRAINDICATIONS

• Severely crushed, mangled, or avulsed parts (avulsion injury - "degloving" from ring avulsion)
• Prolonged ischaemia (>6 hours warm, >12-24 hours cold for digits; lower tolerance for proximal amputations due to muscle mass)
• Multilevel injury
• Hemodynamically unstable patient
• Severe associated injuries (prioritise life over limb)

• Single digit amputation (zone II)
• Extreme contamination
• Patient age (elderly with comorbidities - poor rehabilitation potential)
• Patient preference/occupation

---

V. ISCHAEMIA TIME LIMITS

---

VI. TRANSPORT OF AMPUTATED PART

1. Wrap amputated part in moist normal saline gauze
2. Place in a sealed plastic bag
3. Place bag in ice-water mixture (0-4°C)
4. Never place part directly on ice (causes frostbite)
5. Never use dry ice (causes frostbite)

---

VII. SEQUENCE OF REPLANTATION (MNEMONIC: B-B-T-A-V-N-S)

1. B - Bone shortening and fixation (K-wires, mini-plates, intramedullary wires)
2. B - Back of hand (Extensor tendons) repair
3. T - Tendons (Flexor) repair
4. A - Arteries - microsurgical repair (usually at least one artery)
5. V - Veins - microsurgical repair (2:1 ratio of veins to arteries preferred)
6. N - Nerves - coaptation (immediate or delayed)
7. S - Skin - closure (split-thickness skin graft if needed; no tension)

• Bone stabilization first provides a stable platform for vascular repair
• Arterial repair done before venous to reduce ischaemia time
• Some surgeons do rapid arterial shunting first (temporary intraluminal shunt) to restore perfusion while doing bone/tendon work

---

VIII. SURGICAL TECHNIQUE - KEY POINTS

• Two teams simultaneously: one prepares patient/recipient site, one prepares amputated part
• Regional anesthesia preferred (sympathectomy effect → vasodilation)
• Anticoagulation: heparin intraoperatively

• Shorten by 1-2 cm to relieve tension on vessels/nerves
• K-wire or mini-plate fixation

• Operating microscope (6-40x magnification)
• 10-0 or 11-0 monofilament nylon (Prolene/nylon) sutures
• Interrupted sutures for vessel anastomosis
• Vessel ends cut clean, adventitia stripped 2-3 mm
• Papaverine/lignocaine to relieve vasospasm
• Repair arteries first, then veins
• Must repair minimum 1 artery and 2 veins per digit

• End-to-end coaptation with 9-0 or 10-0 nylon
• Epineural sutures
• If gap >3 cm: nerve graft (sural nerve)

• Hourly checks of capillary refill, colour, temperature, turgor
• Temperature difference >2°C between replanted and normal digit = vascular compromise
• Doppler ultrasound for vessel patency
• Anticoagulation: aspirin, heparin, low molecular weight dextran (dextran-40)
• Warm environment (25-28°C) to prevent vasospasm
• No smoking (nicotine causes vasospasm)
• Elevation to reduce oedema

---

IX. POSTOPERATIVE COMPLICATIONS

---

X. FUNCTIONAL OUTCOMES

• Overall digit survival rate: 80-90% (modern series)
• Two-point discrimination: Median 8-12 mm (normal <6 mm)
• Grip strength: ~60-70% of normal
• Thumb replantation: Best functional results
• Children: Best recovery (neuroplasticity, growth potential)
• Prognostic factors for good outcome:
  • Sharp/guillotine amputation (vs crush/avulsion)
  • Distal level
  • Young age
  • Short ischaemia time
  • Experienced microsurgical team

---

XI. REHABILITATION

• Phase 1 (0-4 weeks): Immobilization, wound care, oedema control
• Phase 2 (4-8 weeks): Gentle active and passive range-of-motion exercises
• Phase 3 (8-12 weeks): Strengthening, desensitization
• Phase 4 (3-12 months): Functional retraining, vocational rehabilitation
• Tenolysis, nerve decompression, or secondary tendon grafting may be required at 6-12 months if function inadequate

---

---

QUESTION 1 (10 marks)

Differential Diagnosis of Tender Scrotal Swelling

---

APPROACH

---

I. TESTICULAR TORSION

• Intravaginal (bell-clapper) torsion: Commonest in adolescents (peak 12-18 years), but can occur at any age; abnormal posterior anchoring of testis allows twisting within tunica vaginalis
• Clinical features: Sudden severe scrotal/groin/lower abdominal pain, nausea, vomiting; high-riding testis with horizontal (transverse) lie; absent cremasteric reflex; exquisite tenderness; later oedema and erythema
• Extravaginal torsion: Seen in neonates (70% prenatal, 30% postnatal)
• Investigation: Colour Doppler ultrasound shows absent blood flow (though clinical diagnosis should never be delayed for imaging if suspicion is high)
• Management: Emergency surgical exploration within 6 hours; detorsion + assessment of viability; bilateral three-point fixation (orchidopexy) if viable; orchidectomy if frankly gangrenous

II. TORSION OF APPENDIX TESTIS / APPENDIX EPIDIDYMIS

• Common in boys aged 7-14 years
• Mild-to-moderate localized pain, usually without vomiting
• Tender nodule at upper pole of testis; "blue dot sign" (infarcted appendage visible through skin) is pathognomonic
• Doppler shows preserved testicular flow
• Managed conservatively - analgesia and rest; exploration reserved for diagnostic uncertainty

III. EPIDIDYMO-ORCHITIS

• Most common cause of acute scrotal pain in adults
• Aetiology: Ascending infection - Chlamydia trachomatis and Neisseria gonorrhoeae in young sexually active men; coliforms (E. coli) in older men with BPH/UTI; mumps virus (orchitis, usually unilateral, post-pubertal)
• Features: Gradual onset pain, fever, dysuria, urinary symptoms; scrotum swollen, red, tender; Prehn's sign positive (pain relieved on elevation of testis - distinguishes from torsion, though unreliable)
• Cremasteric reflex usually preserved
• Management: Antibiotics (doxycycline/ceftriaxone for STI cause, quinolones for coliform), analgesia, scrotal support, treat partner if STI

IV. STRANGULATED / IRREDUCIBLE INGUINOSCROTAL HERNIA

• Bowel or omentum trapped in scrotum through inguinal canal, becomes ischaemic
• Tender, tense, irreducible swelling extending into the scrotum from the inguinal region; cough impulse absent
• Associated with obstruction (vomiting, distension) if bowel involved
• Emergency surgery required to prevent bowel gangrene

V. TORSION OF A TESTICULAR TUMOUR / BLEED INTO A TUMOUR

• A pre-existing testicular tumour may undergo torsion, infarction, or haemorrhage, presenting acutely with pain and tenderness
• Should be suspected if a firm, irregular mass is palpable in addition to tenderness

VI. TRAUMATIC HAEMATOCELE / TESTICULAR RUPTURE

• History of direct scrotal trauma
• Rapid swelling, ecchymosis, severe tenderness
• Ultrasound to assess tunica albuginea integrity
• Surgical exploration and repair if rupture confirmed

VII. IDIOPATHIC SCROTAL OEDEMA

• Seen in prepubertal boys
• Bilateral, erythematous, oedematous, itchy scrotal skin; underlying testis normal and non-tender on deep palpation
• Self-limiting; supportive treatment

VIII. FOURNIER'S GANGRENE (Necrotising Fasciitis of Scrotum)

• Polymicrobial synergistic infection (aerobic + anaerobic) of scrotal/perineal fascia
• Risk factors: diabetes, immunosuppression, local trauma/instrumentation
• Rapidly progressive pain out of proportion to visible signs, crepitus, skin necrosis, systemic sepsis
• Surgical emergency - urgent wide debridement + broad-spectrum IV antibiotics

IX. INFECTED / INFLAMED HYDROCELE (secondary infection)

• A pre-existing hydrocele can become secondarily infected, producing tenderness and warmth

X. HENOCH-SCHÖNLEIN PURPURA (Scrotal involvement)

• Vasculitic scrotal swelling and tenderness in children, associated with purpuric rash, abdominal pain, arthralgia

---

SUMMARY TABLE (Differentiating features)

---

---

QUESTION 2 (10 marks)

Screening Methods and Prognostic Factors of Breast Carcinoma

---

I. SCREENING METHODS

A. Aim of Screening

B. Methods

• Standard screening test; randomized controlled trials show mammography reduces breast cancer mortality by ~40% in women aged 40+ and 15-20% reduction even in 39-49 age group
• Recommended schedule (general population, average risk):
  • Annual/biennial screening mammography starting age 40-50 (varies by guideline - ACS: 45; USPSTF: 40-50 biennial)
  • Continue until age 74 or as long as life expectancy >10 years
• Limitations: Misses 10-15% of cancers (false negative, especially in dense breasts); false positives leading to unnecessary biopsies

• Combined with digital mammography improves cancer detection rate and reduces false positive recalls, especially in dense breast tissue

• Performed by healthcare provider
• American Cancer Society no longer recommends CBE alone for screening in average-risk women (insufficient evidence of mortality benefit), but still practiced in resource-limited settings

• Monthly self-examination; no proven mortality benefit in RCTs but promotes breast awareness; useful in low-resource settings without mammography access

• Adjunct to mammography, particularly useful in:
  • Dense breast tissue (differentiate cystic vs solid)
  • Younger women (<35 years)
  • Pregnant/lactating women (avoids radiation)
• Not used as primary screening tool in average-risk women

• Recommended as an adjunct to mammography in high-risk women (lifetime risk >20%):
  • BRCA1/BRCA2 mutation carriers
  • Strong family history
  • Prior chest radiotherapy (e.g., for Hodgkin's lymphoma) before age 30
• More sensitive but less specific than mammography; higher false positive rate

• BRCA1/BRCA2 testing in high-risk families (strong family history, early onset, triple-negative, male breast cancer, Ashkenazi Jewish ancestry)
• Positive result → intensive surveillance (annual MRI + mammography) or risk-reducing surgery (prophylactic mastectomy/oophorectomy)

C. Risk Stratification for Screening Intensity

---

II. PROGNOSTIC FACTORS OF BREAST CARCINOMA

A. Disease (Tumour) Factors

B. Patient Factors

C. Nottingham Prognostic Index (NPI)

D. Molecular/Genomic Prognostic Tools

• Oncotype DX, MammaPrint - gene expression profiling assays used to predict recurrence risk and guide decisions on adjuvant chemotherapy, particularly in ER+/HER2- node-negative disease

---

---

QUESTION 3 (20 marks)

Aetiology and Management of Male Infertility

---

INTRODUCTION

---

I. NORMAL PHYSIOLOGY (Brief Basis for Understanding Aetiology)

• Hypothalamus → GnRH → pulsatile release
• Pituitary → LH (stimulates Leydig cells → testosterone) and FSH (stimulates Sertoli cells → spermatogenesis)
• Testes → spermatogenesis (74 days) requires intact axis, normal testicular architecture, and patent duct system for transport

---

II. AETIOLOGY - CLASSIFICATION

A. PRE-TESTICULAR CAUSES (Endocrine/Hypothalamic-Pituitary)

1. Hypogonadotrophic hypogonadism
   • Kallmann syndrome (GnRH deficiency + anosmia)
   • Pituitary tumours/adenomas (prolactinoma - hyperprolactinemia suppresses GnRH)
   • Panhypopituitarism
2. Hyperprolactinemia - suppresses GnRH/LH pulsatility
3. Exogenous causes
   • Anabolic steroid abuse (suppresses HPG axis)
   • Exogenous testosterone therapy (negative feedback suppresses spermatogenesis)
4. Systemic illness/endocrinopathy - thyroid disease, Cushing's syndrome, poorly controlled diabetes
5. Obesity - alters hormone metabolism (aromatization of testosterone to estrogen)

B. TESTICULAR CAUSES (Primary Testicular Failure)

1. Genetic disorders
   • Klinefelter syndrome (47,XXY) - most common genetic cause of male infertility
   • Y-chromosome microdeletions (AZFa, AZFb, AZFc regions)
   • Other chromosomal abnormalities/translocations
2. Cryptorchidism (undescended testis) - even after orchidopexy, impaired spermatogenesis risk remains, especially if bilateral or corrected late
3. Varicocele - most common surgically correctable cause of male infertility; causes local hyperthermia and venous stasis impairing spermatogenesis
4. Testicular torsion (previous, especially if managed late) - loss of testicular tissue/function
5. Orchitis - mumps orchitis (post-pubertal), other viral/bacterial orchitis
6. Testicular trauma
7. Gonadotoxins
   • Chemotherapy (alkylating agents especially)
   • Radiotherapy
   • Environmental toxins (pesticides, heavy metals)
8. Drugs - sulfasalazine, cimetidine, spironolactone, calcium channel blockers, chemotherapeutic agents
9. Heat exposure - saunas, tight clothing, occupational (long-distance drivers), varicocele
10. Sertoli-cell-only syndrome
11. Idiopathic - largest single category; no identifiable cause found in ~30-40% of cases

C. POST-TESTICULAR CAUSES (Obstructive/Transport Disorders)

1. Congenital bilateral absence of vas deferens (CBAVD) - associated with CFTR gene mutations (cystic fibrosis carriers)
2. Vasectomy - iatrogenic, most common cause of obstructive azoospermia
3. Epididymal obstruction - post-infective (chlamydia, gonorrhoea, tuberculosis), congenital
4. Ejaculatory duct obstruction
5. Retrograde ejaculation - diabetic autonomic neuropathy, post-TURP/bladder neck surgery, spinal cord injury, alpha-blocker medications
6. Erectile dysfunction / sexual dysfunction - psychological, vascular, neurological, drug-induced
7. Hypospadias/anatomical abnormalities - impaired deposition of semen
8. Anti-sperm antibodies - post-vasectomy reversal, testicular trauma, infection (breach of blood-testis barrier)

D. IDIOPATHIC

• No identifiable cause despite thorough evaluation - accounts for a substantial proportion of cases; may reflect subtle genetic, epigenetic, or oxidative stress-related sperm dysfunction

---

III. EVALUATION (Brief - relevant to guiding management)

1. History: Duration of infertility, sexual history, past infections (mumps, STIs), surgeries (hernia repair, orchidopexy), medications, occupational/environmental exposure, smoking/alcohol
2. Examination: Testicular size and consistency, presence of varicocele, vas deferens palpation, secondary sexual characteristics, gynaecomastia
3. Semen analysis (WHO criteria) - at least 2 samples, 2-7 days abstinence
   • Parameters: volume, concentration, motility, morphology, vitality
4. Hormonal profile: FSH, LH, testosterone, prolactin, TSH
5. Genetic testing: Karyotype, Y-chromosome microdeletion analysis (if azoospermia/severe oligospermia)
6. Scrotal Doppler ultrasound: Varicocele, testicular volume, structural anomalies
7. Transrectal ultrasound: Ejaculatory duct obstruction, seminal vesicle abnormalities
8. Testicular biopsy: Differentiates obstructive vs non-obstructive azoospermia
9. Anti-sperm antibody testing
10. Post-ejaculatory urinalysis: Retrograde ejaculation

---

IV. MANAGEMENT

A. General/Lifestyle Measures

1. Weight loss if obese
2. Cessation of smoking, alcohol, recreational drug use
3. Avoid excessive heat exposure (saunas, hot tubs, tight underwear, laptop on lap)
4. Stop offending medications where possible
5. Treat systemic illness (diabetes control, thyroid correction)
6. Antioxidant supplementation (vitamin E, C, zinc, coenzyme Q10, selenium) - evidence limited but commonly used for idiopathic cases

B. Medical Management

C. Surgical Management

D. Assisted Reproductive Techniques (ART)

E. Preventive Measures

1. Prompt treatment of STIs to prevent epididymal scarring
2. Mumps vaccination (reduces risk of post-pubertal mumps orchitis)
3. Early correction of cryptorchidism (before age 1-2 years, per current guidelines)
4. Fertility preservation (sperm banking) before chemotherapy/radiotherapy or gonadotoxic treatment
5. Genetic counselling for couples with identified genetic causes (Klinefelter, CFTR mutations, Y-microdeletions) before proceeding with ART, given risk of transmission

---

V. PROGNOSIS

• Varicocelectomy improves semen parameters in 60-80% of appropriately selected men, with pregnancy rates improving in a significant proportion
• Vasovasostomy patency rates 70-99% depending on time since vasectomy; pregnancy rates 30-70%
• Non-obstructive azoospermia (genetic/testicular failure) has the poorest prognosis; Micro-TESE sperm retrieval rates vary 40-60% depending on underlying histology
• Idiopathic infertility often managed empirically with ART (IUI/IVF/ICSI) given lack of a correctable target

---

---

QUESTION 1 (30 marks)

Laparoscopic Ventral Hernia Repair

---

INTRODUCTION

---

I. PRINCIPLES

1. Tension-free repair with wide mesh overlap (minimum 3-5 cm beyond defect margins in all directions)
2. Mesh placed intraperitoneally (IPOM) unless defect can be closed, in which case retromuscular/preperitoneal placement is preferred
3. Defect closure whenever feasible, before or after mesh placement, to reduce seroma/bulge and eventration
4. Adequate adhesiolysis to fully visualize the entire defect and rule out "Swiss-cheese" multiple defects

---

II. INDICATIONS

• Primary ventral/umbilical hernias
• Incisional hernias with defect <10 cm (ideal for small-to-moderate sized defects)
• Multiple/multisite defects ("Swiss cheese" defects) - excellent indication, since laparoscopy visualizes the entire abdominal wall
• Recurrent hernias after open repair
• Patients at high risk of wound complications (obesity, diabetes, immunosuppression) benefit most since laparoscopy avoids large skin flaps

---

III. CONTRAINDICATIONS

• Intolerance of pneumoperitoneum or general anaesthesia
• Open/contaminated abdominal wounds
• Poor skin and soft tissue quality requiring resection (e.g., large redundant skin/panniculus needing panniculectomy)

• Extensive intra-abdominal adhesions (from multiple prior laparotomies)
• Severe COPD or heart failure (poor pneumoperitoneum tolerance)
• Large hernia defects >10 cm (harder to achieve adequate overlap/closure laparoscopically)
• Loss of domain (large chronic hernias where herniated contents cannot be safely reduced)

---

IV. PREOPERATIVE PREPARATION

1. CT abdomen/pelvis to define defect size, number of defects, loss of domain, and mesh planning
2. Weight loss/optimization in obese patients
3. Smoking cessation
4. Optimize diabetes control (HbA1c <8)
5. Bowel preparation is not routinely required but may be considered if extensive adhesiolysis anticipated
6. Prophylactic antibiotics (single dose, covering skin flora) at induction
7. Foley catheter and orogastric tube for decompression

---

V. SURGICAL TECHNIQUE

A. Access and Port Placement

• Off-midline entry to avoid the hernia and prior scars
• Hasson open cut-down technique, Veress needle, or optical trocar entry - commonly at Palmer's point (left upper quadrant, 3 cm below costal margin in midclavicular line) or the corresponding right-sided point
• Additional ports placed laterally under vision, generally in a semicircular fan pattern around the defect, with at least one port on the contralateral side to assist with mesh fixation

B. Adhesiolysis

• Careful lysis of adhesions to completely free the anterior abdominal wall and expose the entire defect (or all defects)
• Visceral injury during adhesiolysis is the most feared complication - use sharp dissection preferentially over energy devices near bowel

C. Defect Management

• Bridging repair (older technique): Mesh placed with wide overlap without closing the defect - now largely abandoned as primary technique except for multiple "Swiss-cheese" defects, due to risk of bulging/pseudorecurrence
• Defect closure (preferred, current standard): Fascial defect closed primarily using percutaneous transfascial sutures with a suture-passer device, before mesh placement
  • Reduces seroma formation
  • Effect on long-term recurrence still debated
  • Can be aided by endoscopic component separation for larger defects

D. Mesh Selection and Fixation

• Mesh must have an anti-adhesive barrier (tissue-separating mesh) on the visceral side since it lies in direct contact with bowel:
  • ePTFE (expanded polytetrafluoroethylene)
  • Composite meshes with absorbable barriers (collagen, cellulose, hyaluronate) over polypropylene or polyester
  • Biologic meshes (acellular dermal matrix) in contaminated fields
• Mesh sized with adequate overlap (minimum 3-5 cm, ideally 5 cm circumferentially) beyond defect edges
• Fixation methods:
  • Transfascial sutures (four-point or circumferential)
  • Tacks/staples (absorbable or permanent) - "double-crown" technique (inner and outer rows of tacks)
  • Combination of sutures + tacks provides most secure fixation and reduces recurrence

E. Robotic-Assisted Ventral Hernia Repair (Growing Modality)

• Allows reliable intracorporeal suturing for fascial defect closure and even retromuscular (Rives-Stoppa type) mesh placement laparoscopically/robotically
• Enables robotic transversus abdominis release (r-TAR) - combines minimally invasive access with the myofascial advancement benefits of posterior component separation
• Advantages: superior dexterity and suturing ability compared to straight-stick laparoscopy; increasingly preferred for complex repairs

---

VI. POSTOPERATIVE CARE

• Early mobilization and ambulation
• Abdominal binder to reduce seroma/dead space
• Avoid heavy lifting for 4-6 weeks
• Monitor for early recognition of missed enterotomy (fever, tachycardia, worsening pain 2-4 days postop - can present as delayed peritonitis due to thermal injury from energy devices)

---

VII. ADVANTAGES OF LAPAROSCOPIC OVER OPEN VHR

1. Decreased blood loss
2. Lower wound infection/SSI rates - most consistently demonstrated benefit
3. Decreased hospital stay
4. Better cosmesis, patient preference
5. Ability to identify and treat multiple/occult defects simultaneously
6. Avoids large skin flap elevation (reduces devascularization of subcutaneous tissue)

---

VIII. DISADVANTAGES / LIMITATIONS

1. Has not clearly reduced hernia recurrence rate compared to open repair
2. Seromas (minor SSOs) more common than with open repair
3. Risk of unrecognized enterotomy during adhesiolysis - potentially devastating, delayed presentation
4. Technically demanding - steep learning curve for intracorporeal suturing
5. Risk of pseudorecurrence/bulging if defect not closed (bridging technique)
6. Higher cost of laparoscopic mesh and fixation devices
7. Limited utility for very large defects or loss of domain

---

IX. COMPLICATIONS AND THEIR PREVENTION

---

X. RECENT TRENDS

• Increasing preference for hybrid approaches (laparoscopic-assisted component separation with open fascial closure)
• Robotic TAR becoming the preferred minimally invasive technique for complex/large hernias, since it replicates open retromuscular repair principles with minimally invasive access
• Growing use of enhanced-view totally extraperitoneal (eTEP) approach for retromuscular mesh placement without entering the peritoneal cavity

---

---

QUESTION 2 (10 marks)

Human Skin Bank and Skin Donation

---

I. DEFINITION AND RATIONALE

---

II. SOURCE OF DONOR SKIN

• Cadaveric (deceased) donors - the principal source
• Living donors - only small amounts (e.g., split-thickness graft from unaffected areas of a burns patient, or discarded skin from abdominoplasty/breast reduction surgeries - "living donor" skin)

---

III. DONOR SELECTION CRITERIA

1. Age typically 18-65 years (varies by protocol)
2. No history of transmissible disease: HIV, Hepatitis B/C, syphilis, active infection, sepsis
3. No history of malignancy (especially skin cancer, haematological malignancy)
4. No autoimmune skin disease
5. Death to procurement interval ideally <24 hours (with refrigeration of the body)
6. Informed consent from next of kin (or documented prior donor consent)
7. Serological screening: HIV 1/2, HBsAg, anti-HBc, anti-HCV, syphilis (VDRL/TPHA), sometimes HTLV
8. Microbiological culture of procured tissue

---

IV. PROCUREMENT (RETRIEVAL) PROCESS

1. Skin harvested using a dermatome, typically from the back, thighs, and abdomen
2. Split-thickness grafts (0.3-0.5 mm thickness) harvested under aseptic conditions
3. After procurement, the donor body is covered with absorbent pads/Tyvek garments and sealed to prevent leakage - maintaining dignity of the donor
4. Harvested skin transported to the tissue bank in sterile containers under cold chain

---

V. PROCESSING AND PRESERVATION METHODS

---

VI. QUALITY CONTROL

• Microbiological testing (bacterial, fungal) of every batch
• Serological re-testing at time of donation
• Histological assessment of graft quality
• Regulatory oversight (in India: National Organ and Tissue Transplant Organisation - NOTTO guidelines; internationally: American Association of Tissue Banks - AATB)

---

VII. CLINICAL USES OF SKIN ALLOGRAFTS

1. Major burns (primary indication) - temporary biological dressing for extensively burned patients where autograft donor sites are insufficient
   • Provides wound coverage, reduces fluid/protein loss, reduces infection risk, reduces pain
   • Facilitates early excision and grafting strategy
2. Chronic/hard-to-heal wounds - diabetic ulcers, venous ulcers
3. Temporary coverage after escharectomy while awaiting autograft availability or donor site healing
4. Test graft prior to definitive autografting (assess wound bed readiness)
5. Adjunct in reconstructive surgery (hernia repair using acellular dermal matrix, breast reconstruction)

---

VIII. ADVANTAGES OF ALLOGRAFT SKIN

• Immediately available (unlike autograft requiring donor site)
• Reduces evaporative water loss and heat loss
• Provides mechanical barrier against infection
• Reduces pain
• Improves wound bed vascularity, preparing for later autografting

IX. LIMITATIONS

• Ultimately rejected by host immune system (allograft, not permanent) - typically within 2-4 weeks unless patient is immunosuppressed
• Risk of disease transmission if screening inadequate (rare with modern protocols)
• Limited supply relative to demand (major limiting factor globally)
• Cost of banking infrastructure

---

X. SKIN BANKING IN INDIA

• National Skin Bank programs exist in select burn centres (e.g., LTMG Hospital Mumbai - first skin bank in India, established 2000)
• Programs are growing but remain limited relative to burn injury burden
• Community awareness and organ/tissue donation pledges (similar to eye/organ donation) are being promoted to expand donor pool

---

---

QUESTION 3 (10 marks)

Targeted Therapy for Cancer

---

I. CONCEPT

---

II. RATIONALE

• Cytotoxic chemotherapy/radiation kills tumour cells but also damages normal tissue, causing significant toxicity
• Targeted agents exploit specific molecular abnormalities present in cancer cells but largely absent in normal cells, improving the therapeutic index
• Proof of principle: imatinib, a tyrosine kinase inhibitor of BCR-ABL1 in chronic myeloid leukaemia (CML), produced prolonged remissions, transforming CML from a fatal disease into a chronic manageable condition

---

III. CLASSES OF TARGETED THERAPY

A. Monoclonal Antibodies (block cell-surface receptors/ligands)

B. Small-Molecule Tyrosine Kinase Inhibitors (TKIs)

C. PARP Inhibitors (exploit synthetic lethality)

D. mTOR Inhibitors

• Everolimus, Temsirolimus - renal cell carcinoma, neuroendocrine tumours

E. Immune Checkpoint Inhibitors (targeted immunotherapy)

F. Hormonal/Endocrine Targeted Therapy

• Tamoxifen, Aromatase inhibitors (ER-positive breast cancer)
• Androgen deprivation therapy, Enzalutamide, Abiraterone (prostate cancer)

G. Antibody-Drug Conjugates (ADCs)

• Trastuzumab-emtansine (T-DM1), Trastuzumab-deruxtecan - deliver cytotoxic payload directly to HER2+ cells

---

IV. REQUIREMENT FOR MOLECULAR TESTING

• Targeted therapy requires companion diagnostic testing to confirm the presence of the target before treatment:
  • HER2 IHC/FISH before trastuzumab
  • EGFR mutation testing before erlotinib/osimertinib
  • BRCA1/2 testing before PARP inhibitors
  • KRAS/NRAS/BRAF testing before anti-EGFR therapy in colorectal cancer

---

V. ADVANTAGES

1. Improved specificity - reduced off-target toxicity compared to cytotoxic chemotherapy
2. Can be combined with chemotherapy or used as maintenance therapy
3. Some agents convert previously fatal cancers into chronic manageable diseases (e.g., CML with imatinib)
4. Oral formulations available for many TKIs (convenience)

---

VI. LIMITATIONS / CHALLENGES

1. Drug resistance - tumours develop resistance via secondary mutations in the target (e.g., T790M in EGFR) or activation of bypass pathways; this is the principal reason targeted therapy rarely achieves permanent cure
2. High cost, limiting accessibility
3. Requires tumour genomic profiling - not always feasible/available
4. Not all tumours have a targetable driver mutation
5. Toxicities specific to the pathway blocked (e.g., hypertension/proteinuria with anti-VEGF agents; skin rash with EGFR inhibitors; cardiotoxicity with trastuzumab)

---

VII. FUTURE DIRECTIONS

• Combination targeted regimens (targeting multiple pathways simultaneously to prevent resistance)
• Liquid biopsy for real-time monitoring of resistance mutations
• CAR-T cell therapy for haematological malignancies
• Bispecific antibodies and next-generation ADCs

---

---

QUESTION 4 (30 marks)

Recent Advances in the Management of Incisional Hernia

---

INTRODUCTION

---

I. PREVENTIVE ADVANCES (Reducing Incisional Hernia Incidence)

A. Closure Technique

• Small bites technique for midline laparotomy closure (Jenkins' rule / STITCH trial evidence): continuous mass closure using small tissue bites (5-8 mm), sutures placed close together (5 mm apart), with suture-to-wound length ratio >4:1, using slowly absorbable monofilament suture - significantly reduces incisional hernia rates compared to traditional large-bite closure

B. Prophylactic Mesh Augmentation

• Placement of mesh (usually retromuscular/onlay) at time of primary laparotomy closure in high-risk patients (obesity, AAA repair, stoma reversal)
• Meta-analyses confirm reduced incisional hernia rates in high-BMI patients with prophylactic mesh, without significantly increased wound complication rates
• Network meta-analyses (2023) suggest retro-rectus (sublay) prophylactic mesh position may offer the best balance of efficacy and complication profile

C. Risk Stratification Tools

• Validated risk calculators (e.g., using BMI, prior hernia, wound class, comorbidities) to identify patients for prophylactic mesh or enhanced closure technique

---

II. ADVANCES IN MESH TECHNOLOGY

---

III. ADVANCES IN SURGICAL TECHNIQUE

A. Component Separation Techniques

• Release of external oblique aponeurosis lateral to rectus sheath
• Allows medialization of rectus muscles for midline closure of large defects
• Disadvantage: extensive skin flap elevation → high wound complication rate (skin necrosis, seroma)

• Division of the transversus abdominis muscle in the retrorectus plane, preserving neurovascular bundles to the rectus muscle
• Creates a large retromuscular space for wide mesh placement (sublay) without extensive skin flap elevation
• Significantly reduces wound complications compared to ACS while achieving comparable myofascial advancement
• Now considered a preferred approach for complex/large incisional hernias in major hernia centres
• 2023 systematic review/meta-analysis comparing anterior vs posterior component separation (TAR) for complex incisional hernias shows TAR associated with lower wound complications and comparable recurrence

B. Minimally Invasive Component Separation

• Endoscopic/laparoscopic component separation - performed through small ports/balloon dissection, avoiding large skin flaps while achieving myofascial release
• Robotic transversus abdominis release (r-TAR) - major recent advance: combines the reconstructive benefits of open TAR with minimally invasive access; enables intracorporeal suturing for reliable fascial closure and mesh placement
• Enhanced-view totally extraperitoneal (eTEP) repair - allows retromuscular mesh placement laparoscopically/robotically without violating the peritoneal cavity, reducing risk of visceral injury/adhesions

C. Laparoscopic/Robotic IPOM-Plus

• IPOM (intraperitoneal onlay mesh) combined with primary defect closure ("IPOM-plus") before mesh placement - now standard of care over bridging repair alone

D. Hybrid Approaches

• Combination of laparoscopic adhesiolysis/component separation with open midline fascial closure - balances minimally invasive benefits with reliable defect closure

---

IV. MANAGEMENT OF CONTAMINATED/COMPLEX FIELDS

• Ventral Hernia Working Group (VHWG) and modified CDC wound classification guide mesh choice:
  • Clean (Grade 1): synthetic mesh (permanent)
  • Potentially contaminated (Grade 2): synthetic mesh (lightweight/macroporous) still generally safe
  • Contaminated (Grade 3): biosynthetic/biologic mesh preferred
  • Infected (Grade 4): biologic mesh or staged repair with delayed reconstruction
• Negative pressure wound therapy (NPWT) as an adjunct in contaminated fields and for prevention of surgical site occurrences

---

V. ENHANCED RECOVERY AND PERIOPERATIVE ADVANCES

1. ERAS (Enhanced Recovery After Surgery) protocols applied to abdominal wall reconstruction - multimodal analgesia, early mobilization, optimized fluid management
2. Preoperative optimization: Weight loss programs, smoking cessation, botulinum toxin A injection into lateral abdominal wall muscles (external/internal oblique, transversus abdominis) 2-4 weeks preoperatively to achieve chemical component separation - facilitates fascial closure of large defects, reduces need for extensive component separation surgery
3. Preoperative progressive pneumoperitoneum (Goñi Moreno technique) - gradual insufflation over days to weeks in massive/loss-of-domain hernias, stretching the abdominal wall and increasing abdominal cavity capacity to accommodate reduction of herniated viscera, reducing risk of abdominal compartment syndrome postoperatively
4. Transversus abdominis plane (TAP) blocks / rectus sheath blocks for postoperative analgesia, reducing opioid requirement

---

VI. MANAGEMENT OF LOSS OF DOMAIN (Giant Incisional Hernias)

• Combination of preoperative progressive pneumoperitoneum + botulinum toxin injection to maximize chance of fascial closure
• Component separation (anterior, posterior/TAR, or combined) tailored to defect size
• Tissue expanders in select cases
• Staged abdominal wall reconstruction if primary closure not achievable

---

VII. RECURRENCE PREVENTION - CURRENT BEST EVIDENCE

• Retromuscular (sublay) mesh placement is associated with the lowest recurrence rates among all mesh positions (network meta-analyses)
• Adequate mesh overlap (minimum 5 cm circumferentially)
• Mesh fixation combining sutures and tacks
• Defect closure prior to mesh reinforcement (rather than pure bridging) wherever feasible

---

VIII. EMERGING/INVESTIGATIONAL AREAS

1. 3D-printed patient-specific mesh based on CT-defined defect geometry
2. Biomechanical modelling to predict optimal component separation strategy preoperatively
3. Regenerative medicine approaches - mesenchymal stem cell-seeded scaffolds to improve native tissue regeneration
4. Long-term registries (e.g., Americas Hernia Society Quality Collaborative - AHSQC) driving evidence-based, individualized decision-making

---

IX. SUMMARY OF KEY RECENT ADVANCES

---